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In order to identify the gene encoding the Epstein-Barr virus (EBV) DNA polymerase, a portion of the
BamHI-A fragment containing the fifth leftward open reading frame (BALF5) of the EBV genome was cloned
into SP6 and T7 promoter-containing vectors for in vitro transcription-translation. The RNA synthesized in
vitro was used to program rabbit reticulocyte lysates, which were analyzed for the synthesis of the putative
polymerase polypeptide (110 kDa) and assayed directly for EBV DNA polymerase activity. The polypeptide
synthesized by the full-length BALF5 genomic fragment had a molecular mass of 110 kDa. 5'-truncated BALF5
with the first and second ATGs deleted produced 95- and 83-kDa polypeptides, respectively. All three
translation products were enzymatically active and displayed resistance to high salt concentrations. The
identity of the largest polypeptide as the viral polymerase was established by (i) immunoprecipitation with
EBV-positive sera from patients with nasopharyngeal carcinoma and by a rabbit polyclonal antiserum
prepared with a synthetic peptide derived from the DNA sequence of BALF5; (ii) identification of a polypeptide
of identical size (110 kDa) immunoprecipitated from superinfected Raji cell extracts by these antibodies; and
(iii) salt-resistant enzymatic activity which was neutralized by the rabbit EBV antiserum. Thus, BALF5
encodes a functional polymerase identical to that induced in superinfected Raji cells.
We have had a long-standing interest in Epstein-Barr virus
(EBV) DNA polymerase because of the interaction between
this enzyme and antiviral drugs (2, 5, 10-14). Since EBV
DNA polymerase is essential for viral replication, the study of
this enzyme should provide information useful for the rational
design of drugs for antiviral chemotherapy and a deeper
understanding of the control mechanism of EBV replication.
The EBV DNA polymerase has been tentatively assigned
to the fifth leftward open reading frame (ORF) of the
BamHI-A fragment (BALF5) of the EBV genome. This
determination is based on the sequence homology between
BALF5 and the coding sequences for the herpes simplex
virus type 1 (HSV-1) and human cytomegalovirus DNA
polymerase genes (8, 16) as well as the close match between
the predicted amino acid composition of the BALF5-en-
coded protein (1) and the amino acid composition of partially
purified EBV DNA polymerase (7). In this article, we report
the identification of the EBV DNA polymerase gene and
functional characterization of its encoded enzyme by in vitro
transcription and translation of the cloned gene with the use
of an antiserum specific for EBV DNA polymerase.
BALF5 lying within the EBV EcoRI-C fragment was
isolated by sequential digestion with BglII and EcoRI, fol-
lowed by digestion with SphI to generate a 3.9-kbp fragment
containing the entire BALF5 ORF. The SphI site is 380 bp
upstream of BALF5. The SphI fragment containing BALF5
and a series of 5'-truncated BALF5 fragments were cloned
into pGEM3Z or pGEM2 with the pol gene downstream from
the SP6 or T7 promoter (Fig. 1). Transcription of linearized
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pGEM3Z or pGEM2 yielded uncapped polymerase (pol)
runoff transcripts which were used for in vitro translation.
The major translation product of the full-length pol gene
from pGEM3Z-POL1 and pGEM3Z-POL2 constructs, which
contain three ATGs, migrated as a 110-kDa polypeptide (Fig.
2B, lane 2 and 5). This size corresponds to that of the
predicted product of the pol ORF (1) and the partially
purified EBV pol from an EBV-producing cell line (7;
unpublished data). RNA from pGEM3Z-POL2 was trans-
lated consistently about threefold more efficiently than RNA
from pGEM3Z-POL1. The products of the 5'-truncated
constructs pGEM2-POL3 (Fig. 2B, lane 3) and pGEM3Z-
POL4 (lane 4) could be distinguished from the full-length pol
gene product. Deletion of the first ATG in the pGEM2-POL3
construct resulted in a translation product of 95 kDa (lane 3);
with the pGEM3Z-POL4 construct, which has the first two
ATGs deleted, the translation product was 83 kDa (lane 4).
These translation products (110, 95, and 83 kDa) were
detected only with the sense transcripts and not with either
the antisense or the no-RNA control.
To determine whether the EBV DNA polymerase trans-
lated in vitro could be recognized by EBV-positive serum,
serum from a patient with nasopharyngeal carcinoma (NPC)
with a high titer of early antigen/viral capsid antigen anti-
bodies was used to immunoprecipitate the translation prod-
ucts. Figure 2A clearly shows that this antiserum specifically
recognized polymerase polypeptides of the expected sizes
(110 kDa for both pGEM3Z-POL1 and pGEM3Z-POL2 and
95 and 83 kDa for pGEM2-POL3 and pGEM3Z-POL4,
respectively). EBV-negative serum was unable to precipitate
these polymerase polypeptides (data not shown).
To ascertain whether the in vitro-translated product rep-
resents the authentic polymerase polypeptide, we analyzed
immunoprecipitates of radiolabeled polymerase from super-
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FIG. 1. Construction of four EBV polymerase templates for in
vitro transcription-translation. The SphI fragment (3.9 kbp) contain-
ing the entire BALF5 ORF was isolated from the EBV EcoRI-C
fragment by sequential digestion with appropriate restriction en-
zymes. The 5'-truncated BALF5 fragments were isolated and cloned
into pGEM2 or pGEM3Z. The clones were designated pGEM3Z-











infected Raji cells in parallel with the in vitro-translated
polymerase with serum from an NPC patient. Figure 3 shows
that the human serum precipitated a spectrum of EBV-
specific polypeptides from superinfected Raji cells (panel II,
lane 2). Among these, a 110-kDa polypeptide comigrated
with the in vitro-translated polymerase (lane 3); this poly-
peptide was not detected in mock-infected Raji cells (lane 1).
To further confirm the identity of the 110-kDa polypeptide, a
rabbit antibody prepared by immunization with a synthetic






FIG. 2. Expression of EBV DNA polymerase by in vitro tran-
scription-translation. The templates were linearized at the HindIIl
or EcoRI site, depending on the construct. Transcripts were made
by in vitro transcription of the templates with either SP6 or T7 RNA
polymerase. The pol RNA was translated in rabbit reticulocyte
lysates containing [35S]methionine, and the translated products were
analyzed by electrophoresis and fluorography. (A) Immunoprecipi-
tation of polymerase polypeptides by EBV-positive serum from an
NPC patient. Lane 1, Reticulocyte lysate with no RNA; lane 2,
pGEM3Z-POL1; lane 3, pGEM2-POL3; lane 4, pGEM3Z-POL4;
lane 5, pGEM3Z-POL2. (B) In vitro-translated products. Lane 1,
reticulocyte lysate with no RNA; lane 2, pGEM3Z-POL1; lane 3,
pGEM2-POL3; lane 4, pGEM3Z-POL4; lane 5, pGEM3Z-POL2.
Lane M, Molecular size markers (in kilodaltons).
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FIG. 3. Determination of authenticity of polymerase polypeptide
made in vitro by immunoprecipitation. (I) Immunoprecipitation with
a rabbit antibody (Ab) against synthetic peptide derived from the
DNA sequence of BALF5. Lane 1, mock-infected Raji (MIR) cells;
lane 2, superinfected Raji (SIR) cells; lane 3, in vitro-translated
product of pGEM3Z-POL2. (II) Same samples as in panel I were
immunoprecipitated with serum from an NPC patient. Sizes are
marked in kilodaltons.
for immunoprecipitation. This rabbit antibody specifically
precipitated a 110-kDa polypeptide from both the in vitro-
translated product (Fig. 3, panel I, lane 3) and superinfected
Raji cells (lane 1). These results clearly indicate that the
EBV polymerase from the Raji cells contains the first ATG
of the ORF and the sequence of amino acids downstream of
it.
To ascertain whether the polymerase protein translated in
vitro possessed enzymatic activity, translation mixtures from
transcripts made from these constructs were assayed directly
for EBV DNA polymerase activity (3). The EBV DNA
polymerase from superinfected Raji cells was most active in
the presence of 80 mM ammonium sulfate; therefore, the
translation products were assayed in 80 mM salt. All the pol
constructs produced functional polymerase with enzymatic
activity detectable above the background activity found in the
reticulocyte lysate (Table 1), although the activity was not
stimulated by salt. However, the salt-resistant polymerase
activity was highest in pGEM3Z-POL2, approximately 13-
fold above that in the reticulocyte lysate control. The enzy-
matic activities in pGEM3Z-POL1, pGEM2-POL3, and
pGEM3Z-POL4 were about 6-, 2.2-, and 1.8-fold above the
control level, respectively. A pT7-7.2 construct, containing
the HSV-1 pol gene (3), used as a positive control, exhibited
a property similar to EBV pol in terms of salt-resistant but not
salt-stimulated polymerase activity.
To compare the authentic EBV DNA polymerase made in




TABLE 1. DNA polymerase activity of in vitro-translated
products and cell extractsa
Poypeptid(NH4)2SO Polymerase activity
Polypeptide source (NH480M) (cpm of 32P/100 ptg(80mM) ~ of protein) ± SD
Reticulocyte lysate - 1,400 ± 250
+ 1,250 ± 230
pGEM2-POL1 - 9,440 ± 480
+ 7,950 ± 370
pGEM3Z-POL2 - 20,450 ± 1,130
+ 16,890 ± 890
pGEM2-POL3 - 2,950 ± 390
+ 2,760 ± 410
pGEM2-POL4 - 2,680 ± 310
+ 2,220 ± 280
pT7-7.2b (HSV pol) - 29,270 ± 880
+ 23,660 ± 760
pGEM3Z-POL2 - 1,680 ± 340
(antisense)
+ 1,450 ± 290
Mock-infected Raji cells - 394,800 ± 60,120
+ 212,750 ± 28,930
Superinfected Raji cells - 55,520 ± 7,930
+ 301,750 ± 12,450
a RNA was synthesized by in vitro transcription of linearized templates and
translated in vitro in rabbit reticulocyte lysates as described in the text.
Translation mixtures (25 .1l) were assayed for DNA polymerase activity by
measurement of acid-precipitable radioactivity incorporated by using [a-32P]
dCTP.
b An HSV-1 pol gene clone.
same conditions. The polymerase activity, when assayed in
80 mM ammonium sulfate in superinfected Raji cells, was
approximately 18-fold higher than that of the in vitro-
translated product ofpGEM3Z-POL2. The EBV polymerase
activity in superinfected Raji cells was stimulated approxi-
mately sixfold by salt, in contrast to the cellular polymerase
in mock-infected Raji cells as well as in the reticulocyte
lysate, both of which were inhibited by salt.
The effect of ammonium sulfate on the activity of in
vitro-translated EBV pol was determined and compared with
the effect on the enzymes from superinfected and mock-
infected Raji cells. With increasing salt concentration, the
pol activity from the in vitro-translated product decreased
gradually, with a lag between 80 and 100 mM (Fig. 4). With
further increases in salt concentration up to 180 mM, ap-
proximately 40% of pol activity was retained. In contrast,
the pol activity from superinfected Raji cells showed optimal
salt stimulation at 80 mM salt; at this concentration the pol
activity from mock-infected Raji cells was inhibited approx-
imately 55%. Thus, it appeared that 80 mM salt was optimal
for measuring the salt-resistant pol activity from the in
vitro-translated product and the salt-stimulated pol activity
from superinfected Raji cells.
The inability to demonstrate salt-stimulated polymerase
activity of in vitro-translation product may indicate that
BALF5 encodes only a core polymerase which requires an
additional factor for salt stimulation. EBV early antigen
diffuse component (EA-D) has been implicated as a putative
cofactor (9). Since EA-D is encoded by the BMRF1 ORF of
the EBV genome, BMRF1 was cloned into the pGEM3Z
vector for in vitro transcription and translation. When the
cold translation product ofBMRF1 was included in the DNA
polymerase assay, we were repeatedly unable to demon-
strate salt-stimulated polymerase activity in the presence of
EA-D; in several cases, the polymerase activity was de-
creased by the addition of EA-D (data not shown).
TABLE 2. Effect of antiserum on EBV DNA
polymerase activitya
Polymerase activity %Polypeptide (cpm of 32P/100 pg of protein) ± SD Inhibi-
source
Without antiserum With antiserum tion
Reticulocyte lysate 1,740 ± 130 1,590 ± 120 9
pGEM3Z-POL2 19,940 ± 960 2,990 ± 340 85
Mock-infected Raji cells 167,450 ± 14,250 150,940 ± 17,620 10
Superinfected Raji cells 275,600 ± 30,310 50,632 ± 5,450 82
a Polymerase activities were assayed in the presence of 80 mM (NH4)2SO4.
Prior to assay, the enzyme was incubated with 5 p1 of rabbit antiserum to
polymerase peptide at room temperature for 30 min. The polymerase activity
was then determined as described in the text.
To test whether the rabbit antibody against the synthetic
peptide can neutralize the polymerase activity, active pro-
tein extracts were first incubated with antiserum and then
assayed for polymerization of DNA. The polymerase activ-
ity from superinfected Raji cells and from the cloned gene
product (pGEM3Z-POL2) was inhibited by more than 80%,
in contrast to approximately 10% inhibition observed in
mock-infected Raji cells and reticulocyte lysate (Table 2).
In this study, transcripts made from the BALF5 fragment
(pGEM3Z-POL1) containing the three in-frame ATG initia-
tion codons were translated efficiently into a full-length
polymerase polypeptide (110 kDa). Transcripts made from
5'-truncated templates with deletion of either the first or the
first two ATGs yielded smaller polypeptides (95 and 83 kDa)
(Fig. 2). It appears that the translation ofEBV polymerase in
vivo initiates at the first in-frame ATG, located 12 bp from
the start of BALF5, since a polypeptide (110 kDa) of
identical size and activity was found both in vitro and in
superinfected Raji cells (Fig. 3) and with partially purified
EBV DNA polymerase (7; unpublished data). The 3,045-bp
BALF5 ORF is long enough to encode a 1,015-amino-acid
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FIG. 4. Effect of ammonium sulfate on DNA polymerase activ-
ity. Cell extracts prepared from superinfected (0) and mock-
infected (0) Raji cells and the in vitro translation product of
pGEM3Z-POL2 (AL) were assayed for DNA polymerase activity at
increasing concentrations of (NH4)2SO4. The 100% enzymatic ac-
tivity for mock-infected Raji cells and the in vitro translation
product was determined based on the activity obtained in the
absence of (NH4)2SO4, after substraction of the background,
whereas the 100% activity for superinfected Raji cell extract was
determined based on the concentration of ammonium sulfate (80
mM) at which enzymatic activity was the highest.
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Other direct evidence that the full-length BALF5 ORF is the
coding sequence for the EBV DNA polymerase is provided
by our preliminary RNA analyses with Si nuclease mapping
with primers covering different regions of the genomic
sequence. The results indicated that the protected fragments
all extended beyond the first ATG (6).
While the in vitro-translated polymerase activity was not
stimulated by salt in contrast to that of superinfected Raji
cell extracts, the in vitro-translated product exhibited con-
siderably higher salt-resistant polymerase activity than that
of the endogenous reticulocyte activity. The presence of the
110-kDa polypeptide and the demonstration of polymerase
activity in the in vitro-translated product strongly suggest
that the pol enzymatic activity resides in the 110-kDa poly-
peptide and no additional viral gene products, such as
BMRF1 (EA-D), are necessary to obtain core polymerase
activity in vitro. However, we have not excluded the possi-
bility that BMRF1 or other gene products act as cofactors
that might enhance the polymerase activity in vivo. The lack
of salt-stimulated polymerase activity could be due to the
inherent nature of the in vitro-translated product, similar to
what was found with the cloned gene of HSV-1 pol (3).
Alternatively, the stimulatory effect of salt on the core
polymerase activity may require a modified cofactor such as
the BMRF1 gene product, the effect of which we were not
able to demonstrate in vitro.
Evidence for the authenticity of the polymerase polypep-
tide synthesized in vitro was provided by immunoprecipita-
tion assays and comparison with activity from EBV-infected
cells. Antisera from patients with NPC or prepared against a
synthetic peptide derived from the DNA sequence of
BALF5 precipitated a 110-kDa polypeptide only from super-
infected Raji cells, which comigrated with the polypeptide
precipitated from the in vitro-translated product. Further-
more, the polymerase enzymatic activities from both
sources were inhibited to the same extent by antiserum.
Thus, BALF5 encodes a functional polymerase identical to
that induced in superinfected Raji cells.
The development of a system in which a functional EBV
DNA polymerase can be characterized will help provide a
detailed understanding of the mechanism of viral DNA
replication and its inhibition by antiviral drugs. With this
system, the effect of gene deletions on enzyme activity can
be studied (4, 15, 17), and the functional domains within the
polymerase can be identified and mapped. The present study
is the first step towards these goals.
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